SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

J. Stranne; K. Brasso; B. Brennhovd; E. Johansson; F. Jäderling; M. Kouri; W. Lilleby; P. Meidahl Petersen; T. Mirtti; A. Pettersson; A. Rannikko; C. Thellenberg; O. Akre

doi:10.1080/21681805.2018.1520295

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

J. Stranne^*, K. Brasso, B. Brennhovd, E. Johansson, F. Jäderling, M. Kouri, W. Lilleby, P. Meidahl Petersen, T. Mirtti, A. Pettersson, A. Rannikko, C. Thellenberg, O. Akre

^*Corresponding author for this work

Department of Clinical Medicine

23 Citations (Scopus)

Abstract

Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country’s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.

Original language	English
Journal	Scandinavian Journal of Urology
Volume	52
Issue number	5-6
Pages (from-to)	313-320
Number of pages	8
ISSN	2168-1805
DOIs	https://doi.org/10.1080/21681805.2018.1520295
Publication status	Published - 2018

Keywords

androgen deprivation therapy
Locally advanced prostate cancer
radical prostatectomy
radiotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/21681805.2018.1520295

Cite this

Stranne, J., Brasso, K., Brennhovd, B., Johansson, E., Jäderling, F., Kouri, M., Lilleby, W., Meidahl Petersen, P., Mirtti, T., Pettersson, A., Rannikko, A., Thellenberg, C., & Akre, O. (2018). SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scandinavian Journal of Urology, 52(5-6), 313-320. https://doi.org/10.1080/21681805.2018.1520295

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. / Stranne, J.; Brasso, K.; Brennhovd, B. et al.
In: Scandinavian Journal of Urology, Vol. 52, No. 5-6, 2018, p. 313-320.

Research output: Contribution to journal › Journal article › Research › peer-review

Stranne, J, Brasso, K, Brennhovd, B, Johansson, E, Jäderling, F, Kouri, M, Lilleby, W, Meidahl Petersen, P, Mirtti, T, Pettersson, A, Rannikko, A, Thellenberg, C & Akre, O 2018, 'SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer', Scandinavian Journal of Urology, vol. 52, no. 5-6, pp. 313-320. https://doi.org/10.1080/21681805.2018.1520295

@article{2e9801472d8b433ebcb5fa21a04534ba,

title = "SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer",

abstract = "Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country{\textquoteright}s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.",

keywords = "androgen deprivation therapy, Locally advanced prostate cancer, radical prostatectomy, radiotherapy",

author = "J. Stranne and K. Brasso and B. Brennhovd and E. Johansson and F. J{\"a}derling and M. Kouri and W. Lilleby and {Meidahl Petersen}, P. and T. Mirtti and A. Pettersson and A. Rannikko and C. Thellenberg and O. Akre",

year = "2018",

doi = "10.1080/21681805.2018.1520295",

language = "English",

volume = "52",

pages = "313--320",

journal = "Scandinavian Journal of Urology",

issn = "2168-1805",

publisher = "Taylor & Francis",

number = "5-6",

}

TY - JOUR

T1 - SPCG-15

T2 - a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

AU - Stranne, J.

AU - Brasso, K.

AU - Brennhovd, B.

AU - Johansson, E.

AU - Jäderling, F.

AU - Kouri, M.

AU - Lilleby, W.

AU - Meidahl Petersen, P.

AU - Mirtti, T.

AU - Pettersson, A.

AU - Rannikko, A.

AU - Thellenberg, C.

AU - Akre, O.

PY - 2018

Y1 - 2018

N2 - Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country’s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.

AB - Objective: To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). Materials and methods: SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard (RT + ADT) or experimental (RP with extended pelvic lymph-node dissection and with addition of adjuvant or salvage RT and/or ADT if deemed necessary) treatment. Each centre follows guidelines regarding the timing and dosing of postoperative RT and adjuvant treatment such as ADT The primary endpoint is cause-specific survival. Secondary endpoints include metastasis-free and overall survival, quality-of-life, functional outcomes and health-services requirements. Each subject will be followed up for a minimum of 10 years. Results: Twenty-three centres in Denmark, Finland, Norway and Sweden, well established in performing RP and RT for prostate cancer participated. Each country’s sites were coordinated by national coordinating investigators and sub-investigators for urology and oncology. Almost 400 men have been randomized of the stipulated 1200, with an increasing rate of accrual. Conclusions: The SPCG-15 trial aims to compare the two curatively intended techniques supplying new knowledge to support future decisions in treatment strategies for patients with LAPC The Scandinavian healthcare context is well suited for performing multi-centre long-term prospective randomized clinical trials. Similar care protocols and a history of entirely tax-funded healthcare facilitate joint trials.

KW - androgen deprivation therapy

KW - Locally advanced prostate cancer

KW - radical prostatectomy

KW - radiotherapy

U2 - 10.1080/21681805.2018.1520295

DO - 10.1080/21681805.2018.1520295

M3 - Journal article

C2 - 30585526

AN - SCOPUS:85059091401

SN - 2168-1805

VL - 52

SP - 313

EP - 320

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

IS - 5-6

ER -

SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this